C
35.70
-0.08 (-0.22%)
| Penutupan Terdahulu | 35.78 |
| Buka | 35.21 |
| Jumlah Dagangan | 1,323,519 |
| Purata Dagangan (3B) | 2,212,036 |
| Modal Pasaran | 3,797,552,384 |
| Harga / Pendapatan (P/E TTM) | 43.54 |
| Harga / Pendapatan (P/E Ke hadapan) | 101.01 |
| Harga / Jualan (P/S) | 5.63 |
| Harga / Buku (P/B) | 5.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | 19.55% |
| Margin Operasi (TTM) | 2.17% |
| EPS Cair (TTM) | 1.15 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -26.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.00% |
| Nisbah Semasa (MRQ) | 3.07 |
| Aliran Tunai Operasi (OCF TTM) | 179.44 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 160.08 M |
| Pulangan Atas Aset (ROA TTM) | 9.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 21.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Corcept Therapeutics Incorporat | Menurun | Menurun |
AISkor Stockmoo
1.5
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.49% |
| % Dimiliki oleh Institusi | 80.05% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 100.00 (Canaccord Genuity, 180.11%) | Beli |
| Median | 95.00 (166.11%) | |
| Rendah | 60.00 (HC Wainwright & Co., 68.07%) | Beli |
| Purata | 85.00 (138.10%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 53.77 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Feb 2026 | 60.00 (68.07%) | Beli | 36.22 |
| 20 Feb 2026 | 67.00 (87.68%) | Beli | 34.82 | |
| Canaccord Genuity | 23 Jan 2026 | 100.00 (180.11%) | Beli | 43.98 |
| 02 Jan 2026 | 99.00 (177.31%) | Beli | 38.20 | |
| UBS | 16 Dec 2025 | 95.00 (166.11%) | Pegang | 81.12 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GUYER WILLIAM | 35.97 | - | 996 | 35,826 |
| LYON JOSEPH DOUGLAS | 35.97 | 35.28 | 707 | 25,492 |
| MADUCK SEAN | 35.97 | 35.28 | 798 | 28,780 |
| MOKARI ATABAK | 35.97 | 35.28 | 698 | 25,173 |
| ROBB GARY CHARLES | 35.97 | 35.28 | 877 | 31,629 |
| WILSON JAMES N | 36.48 | 36.48 | -10,636 | -388,001 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,560 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -241,101 | |||
| Purata Pembelian Keseluruhan ($) | 36.06 | |||
| Purata Jualan Keseluruhan ($) | 35.52 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MOKARI ATABAK | Pegawai | 03 Mar 2026 | Dibuang (-) | 96 | 35.28 | 3,387 |
| ROBB GARY CHARLES | Pegawai | 03 Mar 2026 | Dibuang (-) | 121 | 35.28 | 4,269 |
| MADUCK SEAN | Pegawai | 03 Mar 2026 | Dibuang (-) | 110 | 35.28 | 3,881 |
| LYON JOSEPH DOUGLAS | Pegawai | 03 Mar 2026 | Dibuang (-) | 89 | 35.28 | 3,140 |
| MOKARI ATABAK | Pegawai | 02 Mar 2026 | Diperolehi (+) | 794 | 35.97 | 28,560 |
| GUYER WILLIAM | Pegawai | 02 Mar 2026 | Diperolehi (+) | 996 | 35.97 | 35,826 |
| ROBB GARY CHARLES | Pegawai | 02 Mar 2026 | Diperolehi (+) | 998 | 35.97 | 35,898 |
| MADUCK SEAN | Pegawai | 02 Mar 2026 | Diperolehi (+) | 908 | 35.97 | 32,661 |
| LYON JOSEPH DOUGLAS | Pegawai | 02 Mar 2026 | Diperolehi (+) | 796 | 35.97 | 28,632 |
| WILSON JAMES N | Pengarah | 24 Feb 2026 | Dibuang (-) | 100,000 | 36.48 | 3,648,000 |
| WILSON JAMES N | Pengarah | 24 Feb 2026 | Diperolehi (+) | 89,364 | 36.48 | 3,259,999 |
| WILSON JAMES N | Pengarah | 24 Feb 2026 | Pelaksanaan pilihan | 100,000 | - | - |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Jan 2026 | Pengumuman | Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer |
| 31 Dec 2025 | Pengumuman | Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |